Physician profile
Christine L Dombroski
NPI 1457449860
$4,635.68
in general payments reported to CMS, 2019-2025
34 companies · $965 in 2025
The $965 reported for 2025 was more than what 96% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $834 · 2022: $1,095 · 2023: $986 · 2024: $755 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,680 · Education: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,679.82 |
| Education | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $996.89 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $811.59 | 2021-2025 | |
| Astellas Pharma US INC | $322.36 | 2023-2025 | Veozah, Myrbetriq |
| Agile Therapeutics, INC. | $248.84 | 2021-2024 | Twirla |
| Sumitomo Pharma America, INC. | $218.26 | 2023-2025 | Myfembree, Gemtesa |
| Novo Nordisk INC | $184.94 | 2024-2025 | Wegovy |
| Myriad Women'S Health, INC. | $181.17 | 2023 | Myrisk |
| Exeltis, USA INC. | $157.26 | 2021-2025 | Slynd |
| Biogen, INC. | $126.49 | 2024-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $125.68 | 2022 | |
| Therapeuticsmd, INC. | $124.90 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $123.90 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $106.16 | 2021 | |
| Mylan Pharmaceuticals INC. | $90.36 | 2021-2022 | |
| Coopersurgical, INC. | $86.24 | 2021-2024 | Paragard T 380a |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $86.03 | 2021-2022 | |
| Pfizer INC. | $81.89 | 2022-2025 | |
| Organon LLC | $78.93 | 2022-2024 | Nexplanon |
| Aspira Women'S Health INC | $61.11 | 2021-2024 | Ova1 |
| Scynexis, INC. | $59.71 | 2022 | |
| Millicent US INC | $45.46 | 2024-2025 | Intrarosa |
| Daiichi Sankyo INC. | $45.30 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.03 | 2023 | |
| Lilly USA, LLC | $38.15 | 2025 | Zepbound, Mounjaro |
| Shield Therapeutics INC | $37.89 | 2023-2025 | Accrufer |
| Exact Sciences Corporation | $33.00 | 2025 | Cologuard Collection Kit |
| Pacira Pharmaceuticals Incorporated | $19.79 | 2023 | Exparel |
| Myovant Sciences INC. | $17.50 | 2022 | |
| Allergan, INC. | $16.10 | 2021 | |
| Becton, Dickinson and Company | $15.27 | 2024 | Bd Onclarity |
| Currax Pharmaceuticals LLC | $14.91 | 2024 | Contrave |
| Lsi Solutions INC | $14.74 | 2023 | Fornisee |
| Merck Sharp & Dohme LLC | $13.27 | 2021 | |
| Ascend Therapeutics US, LLC | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Dombroski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.